Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print December 16, 2005, doi:10.1212/01.wnl.0000192260.33106.bb)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
01.wnl.0000192260.33106.bbv1
66/1_suppl_1/S20    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Engel, W. K.
Right arrow Articles by Askanas, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engel, W. K.
Right arrow Articles by Askanas, V.
Received ,
Accepted ,

Inclusion-body myositis. Clinical, diagnostic, and pathologic aspects

W. King Engel MD* and Valerie Askanas MD, PhD

From the Neuromuscular Center, Department of Neurology, University of Southern California Keck School of Medicine, Good Samaritan Hospital, Los Angeles, CA.


* To whom correspondence should be addressed. E-mail: askanas{at}hsc.usc.edu.

Abstract--The diagnostic aspects of sporadic inclusion-body myositis (s-IBM), and a few comments on our own approach to its treatment, are presented to foster the goals of this symposium, which was organized to provoke new ideas concerning the cause and treatment of this currently unsolvable disease. s-IBM is the most common, progressive, debilitating muscle disease beginning in persons over age 50 years, and it is more common in men. Diagnostic parameters reviewed are clinical, muscle-biopsy histochemistry, electrophysiologic and CSF evaluations. Overall, the degenerative phenomena in s-IBM muscle fibers seem to be the major cause of the progressive, unstoppable weakness, rather than the lymphocytic inflammation. Available treatments are of only slight, temporary benefit for only some s-IBM patients, indicating a desperate need for definitive therapies.




This article has been cited by other articles:


Home page
 BMJHome page
S. A Greenberg
How citation distortions create unfounded authority: analysis of a citation network
BMJ, July 23, 2009; 339(jul20_3): b2680 - b2680.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. J. Page, J. Y. Suk, L. Bazhenova, S. M. Fleming, M. Wood, Y. Jiang, L. T. Guo, A. P. Mizisin, R. Kisilevsky, G. D. Shelton, et al.
Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins
PNAS, July 7, 2009; 106(27): 11125 - 11130.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. E. Finch
A perspective on sporadic inclusion-body myositis: The role of aging and inflammatory processes
Neurology, January 24, 2006; 66(1_suppl_1): S1 - S6.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
V. Askanas and W. K. Engel
Inclusion-body myositis: A myodegenerative conformational disorder associated with A{beta}, protein misfolding, and proteasome inhibition
Neurology, January 24, 2006; 66(1_suppl_1): S39 - S48.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by AAN Enterprises, Inc.